The Insider, Paul Evangelista Invested in 3 Shares of Century Bancorp, Inc. (CNBKA); ImmunoGen, Inc. (IMGN) Had 6 Bulls

Century Bancorp Inc’s Executive Vice President Paul Evangelista bought 3 shares of the stock exchange listed company in purchase through a broker dated 14-03-2018. Paul Evangelista’s shares were purchased at an average market price per share of $132.6, for a total transaction of $398. In the last month, he also obtained 16 shares with a market value $1,579 USD. The dated 14-03-2018 transaction’s document filed with the Security Exchange Commission is obtainable online here. Now, he owns a total of 5,809 shares or 0.16% of Century Bancorp Inc’s total market cap.

Among 9 analysts covering Immunogen (NASDAQ:IMGN), 6 have Buy rating, 1 Sell and 2 Hold. Therefore 67% are positive. Immunogen had 28 analyst reports since August 3, 2015 according to SRatingsIntel. The rating was maintained by Leerink Swann with “Market Perform” on Monday, May 2. The stock has “Outperform” rating by Oppenheimer on Wednesday, July 29. The firm has “Buy” rating by Canaccord Genuity given on Thursday, February 1. On Sunday, June 4 the stock rating was maintained by Cowen & Co with “Hold”. RBC Capital Markets maintained the stock with “Outperform” rating in Monday, July 27 report. Cantor Fitzgerald maintained the stock with “Hold” rating in Tuesday, May 30 report. The firm has “Outperform” rating given on Thursday, July 6 by RBC Capital Markets. As per Wednesday, October 28, the company rating was maintained by Leerink Swann. The rating was maintained by Cantor Fitzgerald on Tuesday, August 29 with “Hold”. Cantor Fitzgerald downgraded ImmunoGen, Inc. (NASDAQ:IMGN) rating on Monday, August 3. Cantor Fitzgerald has “Neutral” rating and $21 target. See ImmunoGen, Inc. (NASDAQ:IMGN) latest ratings:

08/02/2018 Broker: RBC Capital Markets Rating: Buy New Target: $9.0 Initiate
01/02/2018 Broker: Canaccord Genuity Rating: Buy New Target: $15.0 Maintain
31/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $18 Initiates Coverage On
03/11/2017 Broker: Jefferies Rating: Buy New Target: $11.0 Maintain
03/11/2017 Broker: Canaccord Genuity Rating: Buy New Target: $10.0 Maintain
10/10/2017 Broker: Jefferies Rating: Buy New Target: $9.0 Maintain
02/10/2017 Broker: RBC Capital Markets Rating: Buy New Target: $12.0 Maintain

Investors sentiment increased to 1.38 in 2017 Q3. Its up 0.22, from 1.16 in 2017Q2. It improved, as 16 investors sold ImmunoGen, Inc. shares while 48 reduced holdings. 38 funds opened positions while 36 raised stakes. 87.70 million shares or 19.45% more from 73.42 million shares in 2017Q2 were reported. State Of Wisconsin Invest Board invested in 0% or 58,000 shares. Ngam L P invested 0.02% in ImmunoGen, Inc. (NASDAQ:IMGN). Focused Wealth Inc invested in 100 shares or 0% of the stock. Ameriprise accumulated 208,574 shares. 590,708 are owned by Eam Invsts Ltd Liability. Janney Montgomery Scott Limited Liability has 0.01% invested in ImmunoGen, Inc. (NASDAQ:IMGN). Trexquant Investment Limited Partnership reported 0.2% stake. Tiaa Cref holds 703,892 shares. Carroll Financial Assoc Inc has 209 shares. Amer Intl Group Inc holds 0% or 56,431 shares. Legal General Plc reported 21,526 shares stake. National Bank & Trust Of New York Mellon holds 548,486 shares or 0% of its portfolio. Zacks Invest Mngmt owns 21,774 shares. Pinnacle Associate Ltd holds 0.21% of its portfolio in ImmunoGen, Inc. (NASDAQ:IMGN) for 1.47M shares. The California-based First Republic Invest has invested 0% in ImmunoGen, Inc. (NASDAQ:IMGN).

ImmunoGen, Inc., a clinical-stage biotechnology company, develops targeted anticancer therapeutics. The company has market cap of $1.52 billion. The firm develops its products using its antibody-drug conjugate technology. It currently has negative earnings. The companyÂ’s product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha for the treatment of platinum-resistant ovarian cancer; IMGN529, an ADC that is in Phase 1b/2 clinical trials for B-cell malignancies; coltuximab ravtansine, which is in Phase 2 trials for B-cell malignancies; IMGN779 that is in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML); and IMGN632, a preclinical CD123-targeting ADC for the treatment of hematological malignancies, including AML.

The stock decreased 3.74% or $0.445 during the last trading session, reaching $11.455. About 1.17M shares traded. ImmunoGen, Inc. (NASDAQ:IMGN) has declined 3.49% since March 14, 2017 and is downtrending. It has underperformed by 20.19% the S&P500.

Since February 13, 2018, it had 0 buys, and 10 selling transactions for $2.85 million activity. $228,922 worth of ImmunoGen, Inc. (NASDAQ:IMGN) shares were sold by Johnston David Brannon. 11,713 shares were sold by JUNIUS DANIEL M, worth $140,556 on Wednesday, February 21. Gregory Richard J. sold $375,208 worth of ImmunoGen, Inc. (NASDAQ:IMGN) on Wednesday, February 21. Berkenblit Anna sold $188,540 worth of stock. Shares for $123,804 were sold by Wingrove Theresa on Wednesday, February 21. $129,211 worth of ImmunoGen, Inc. (NASDAQ:IMGN) was sold by Ryll Thomas on Wednesday, February 21. Enyedy Mark J also sold $736,084 worth of ImmunoGen, Inc. (NASDAQ:IMGN) on Wednesday, February 21.

The stock increased 1.28% or $0.975 during the last trading session, reaching $77.375. About 114 shares traded. Century Bancorp, Inc. (NASDAQ:CNBKA) has risen 42.16% since March 14, 2017 and is uptrending. It has outperformed by 25.46% the S&P500.

Since December 12, 2017, it had 30 buys, and 0 selling transactions for $1.24 million activity. $663 worth of Century Bancorp, Inc. (NASDAQ:CNBKA) shares were bought by SLOANE BARRY R. 3 shares were bought by EVANGELISTA PAUL A, worth $398 on Monday, February 12. Filler James J bought $10,690 worth of Century Bancorp, Inc. (NASDAQ:CNBKA) on Friday, March 2. On Friday, February 16 Feeney Brian J. bought $157 worth of Century Bancorp, Inc. (NASDAQ:CNBKA) or 2 shares. On Tuesday, February 20 the insider WESTLING JON bought $1,103. $79 worth of Century Bancorp, Inc. (NASDAQ:CNBKA) was bought by Delinsky Stephen R. Kay Linda Sloane also bought $1,261 worth of Century Bancorp, Inc. (NASDAQ:CNBKA) on Tuesday, February 20.

Century Bancorp, Inc. operates as a bank holding firm for Century Bank and Trust Company that provides banking services and products. The company has market cap of $279.00 million. It accepts savings accounts, NOW accounts, demand deposits, time deposits, and money market accounts, as well as cash management accounts. It has a 19.32 P/E ratio. The firm offers single-family and multi-family residential loans, municipal loans, commercial and residential real estate loans, and various consumer loans, as well as provides loans for the construction of residential homes, multi-family properties, commercial real estate properties, and land development.

Investors sentiment decreased to 1.23 in 2017 Q3. Its down 0.05, from 1.28 in 2017Q2. It fall, as 0 investors sold Century Bancorp, Inc. shares while 25 reduced holdings. 10 funds opened positions while 22 raised stakes. 1.94 million shares or 0.45% less from 1.95 million shares in 2017Q2 were reported. Tokio Marine Asset Ltd has invested 0.1% of its portfolio in Century Bancorp, Inc. (NASDAQ:CNBKA). Moreover, Axa has 0% invested in Century Bancorp, Inc. (NASDAQ:CNBKA) for 13,100 shares. Tiaa Cref Mgmt Ltd Liability holds 8,569 shares or 0% of its portfolio. Delphi Mgmt Inc Ma has invested 0.5% in Century Bancorp, Inc. (NASDAQ:CNBKA). State Common Retirement Fund reported 3,200 shares stake. 17,332 are held by Morgan Stanley. Bnp Paribas Arbitrage Sa holds 0% of its portfolio in Century Bancorp, Inc. (NASDAQ:CNBKA) for 259 shares. California State Teachers Retirement has invested 0% in Century Bancorp, Inc. (NASDAQ:CNBKA). Jacobs Asset Mngmt Ltd Llc, a New York-based fund reported 135,000 shares. Banc Funds Limited Liability Company owns 76,904 shares or 0.28% of their US portfolio. Denali Limited Liability accumulated 0% or 71 shares. Schwab Charles Inv Mgmt holds 11,413 shares. Panagora Asset owns 8,063 shares or 0% of their US portfolio. Numeric Ltd Co has 6,861 shares for 0% of their portfolio. Moreover, Daniel Devine And Communication has 0.78% invested in Century Bancorp, Inc. (NASDAQ:CNBKA) for 12,757 shares.